Alexander Azoy - 09 Mar 2023 Form 3 Insider Report for Arcus Biosciences, Inc. (RCUS)

Role
Chief Accounting Officer
Signature
/s/ Carolyn Tang, Attorney-in-Fact
Issuer symbol
RCUS
Transactions as of
09 Mar 2023
Net transactions value
$0
Form type
3
Filing time
10 Mar 2023, 15:49:56 UTC
Next filing
05 Jul 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding RCUS Common Stock 690 09 Mar 2023 Direct
holding RCUS Common Stock 216 09 Mar 2023 Direct F1
holding RCUS Common Stock 3,187 09 Mar 2023 Direct F2
holding RCUS Common Stock 2,375 09 Mar 2023 Direct F3
holding RCUS Common Stock 5,128 09 Mar 2023 Direct F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding RCUS Stock Option (Right to Buy) 09 Mar 2023 Common Stock 87,500 $21.53 Direct F5
holding RCUS Stock Option (Right to Buy) 09 Mar 2023 Common Stock 867 $31.49 Direct F6
holding RCUS Stock Option (Right to Buy) 09 Mar 2023 Common Stock 8,500 $33.03 Direct F7
holding RCUS Stock Option (Right to Buy) 09 Mar 2023 Common Stock 9,500 $22.02 Direct F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units that were granted on March 8, 2021. The remaining RSUs will vest in two equal annual installments beginning December 15, 2023, subject to the Reporting Person's continued service to the Issuer through such vesting date.
F2 Represents restricted stock units that were granted on March 8, 2022. The remaining RSUs will vest in three equal annual installments beginning December 15, 2023, subject to the Reporting Person's continued service to the Issuer through such vesting date.
F3 Represents restricted stock units that were granted on December 15, 2022. The remaining RSUs will vest in two equal annual installments beginning December 15, 2023, subject to the Reporting Person's continued service to the Issuer through such vesting date.
F4 Represents restricted stock units that were granted on January 23, 2023. The remaining RSUs will vest in four equal annual installments beginning December 15, 2023, subject to the Reporting Person's continued service to the Issuer through such vesting date.
F5 This option was granted on November 9, 2020, with the total number of shares of common stock subject to this option vesting in 48 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer through such vesting date. As of the date of this filing, 45,833 of the shares of common stock subject to this option were exercisable.
F6 This option was granted on March 8, 2021, with the total number of shares of common stock subject to this option vesting in 48 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer through such vesting date. As of the date of this filing, 470 of the shares of common stock subject to this option were exercisable.
F7 This option was granted on March 8, 2022 with the total number of shares of common stock subject to this option vesting in 48 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer through such vesting date. As of the date of this filing, 2,479 of the shares of common stock subject to this option were exercisable.
F8 This option was granted on January 23, 2023, with the total number of shares of common stock subject to this option vesting in 48 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer through such vesting date. As of the date of this filing, 396 of the shares of common stock subject to this option were exercisable.